SUBJECT INDEX VOLUME 25

A cAMP, 836 Dorsal raphe nucleus, 858, 892 Cannabis, 757 Double-blind, 548 Abstinence, 313 Carbamazepine, 729 Drug abuse, 195, 332 Acetylcholine, 555, S85 Catalepsy, 634 Drug addiction, 341 Acoustic startle, 72 Catecholamines, S97 Drug liking, 548 ACTH, 537, 699 CCK2 receptor-deficient mice, 690 Drug model, 455 Addiction, 234, 651 CD151, 729 Drug self-administration, 104, 320 Adenosine A2A receptors, 505 Cerebral cortex, 816 Drug withdrawal, 55 Adolescence, 601, S89 Cerebrospinal fluid, 468 Drug-seeking, 341 Adrenergic receptors, 904 Cholecystokinin-tetrapeptide (CCK-4), 699 Duloxetine, 871 ␣2-Adrenergic receptors, 98 CHPG, 505 Dysphoria, 642 ␣2-Adrenoceptors, 845 Chronobiology, S102 Affect, 277 Cigarette smoking, S89 Aging, 258, 766 Cingulate, S79 E Agmatine, 98 Circadian rhythms, 267 Alcohol, 332, 537 Clinical trial, 402, 713 EEG sleep, S85 Alcohol dependence, 936 Clonidine, 845 EEG spectral analysis, 576 Alcoholism, 332, 936, S45 Clozapine, 149, 410 EEG topography, S57 Allopregnanolone, 489, 576 Cocaine, 28, 104, 195, 320, 332, 440 Efficacy, 713 Allotetrahydrodeoxycorticosterone, 489 Cocaine self-administration, 185 Electroencephalography (EEG), 332, 498 Alpha-2 adrenoceptor agonists, 320 Cognition, 662, 757, 936 Electrophysiology, 858 Alpha-methyl-para-tyrosine, S97 Cognitive, 402 Emission computed, S74 Alzheimer’s disease, 84 Computerized assessment, 766, 777 Encoding, 744 AMPA, 234 Conditioned avoidance response, 634 Energy metabolism, S5 Amphetamine, 55, 157, 789, 925 Conditioned place preference, 41 Episodic memory, 744 Anterior cingulate, 1, 139 Conditioned reinforcement, 440 Estradiol, 242 Anticholinesterase, 555 Conditioned stimulus, 361 Estrogen, 881 Antidepressants, 384, 737, 845, 858 Core body and skin temperatures, S92 Ethogram, 527 Antinociception, 98 Cortisol, 267, 537, 699, 793 Extinction, 185, 320 Antipsychotic drugs, 224, 514, 642 CREB, 836 Extrapyramidal side effects, 514 Antipsychotics, 149, 410, 489, 634 CRF1 receptors, 585 Anxiety, 585, 601, 669, 690 CYP2D6, 737 Anxiolysis, 131 Cytokines, S45 F Appetite, S21 Arithmetic, S68 Facial affect, 915 Arousal, 277 D Fatty acids, S36 Attention, 313 FDG, S74 Attention deficit hyperactivity disorder, D4, 624 Fenfluramine challenge, 395 18 624, 651 D2 `knockout’, 527 F-Fallypride, 476 Auditory, 498 D2 receptor, 634 Fgf stem cell, 805 Autonomic responses, 537 D2 receptors, 498 Fibroblast growth factor, 805 Autoradiography, 624 d-Amphetamine, 548 Fluoxetine, 55, 440, 836 D1-dopamine receptor, 224 fMRI, 925, S85 Dependence, 789 FMRI, S68 B Depersonalization, 793 Fos, 224 Depletion studies, S97 Frontal cortex, 332, 384, 662 Behavioural phenotype, 527 Depression, 55, 267, 384, 395, 836, 871, S21, Functional brain imaging, S50 Benzodiazepines, 585, 744 S74, S79, S89, S102 Functional imaging, 165 Biochemical marker, 84 Depressive disorders, 737, S40, S97 Functional MRI, 915, S79 Biological rhythms, S21 Dexamethasone, 793 Bipolar disorder, 608, 713, 729 Diagnosis, 373 Body weight, 55 Differential display, S28 G Brain, 555 Discriminative stimulus, 361 Brain mapping, 925 Dissociation, 793 GABA, 489, 699, 704 Brain repair, 816 Divided attention, S68 GABAA receptor, 576 Brain stimulation reward, 234 Dominance-subordination, 277 GBR-12909, 28 Brain-derived neutrotrophic factor, 258 Dopamine, 1, 28, 149, 157, 204, 213, 234, 361, Gender, 258, S89 Buprenorphine, 104 384, 440, 468, 624, 634, 642, 679, 704, Gene expression, 185 Bupropion SR, 131 789, S97 Genetics, 608 Buproprion, 440 Dopamine D2 receptors, 213, 505, 527 Geriatric psychiatry, 737 Dopamine D-2 receptors, 476 Globus pallidus, 28 Dopamine receptors, 423, 904, 514 Glucocorticoids, 881 C Dopamine reuptake inhibitor, 104 Glucose metabolism, S50 Dopaminergic, 139 Glutamate, 157, 173, 234, 242, 455, 662, Caesarean section, 423 Dorsal hippocampus, 662 704, 936

NEUROPSYCHOPHARMACOLOGY 2001–VOL. 25, NO. 6 © 2001 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/01/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(01)00380-3

952 Subject Index NEUROPSYCHOPHARMACOLOGY 2001–VOL. 25, NO. 6

Glutamate receptors, 341 M Orexin, S5, S14 Gonadal hormones, 118 Oscillation, 28 Grade of membership classification, 373 Magnetoencephalography (MEG), 498 Ovariectomy, 242 Guanfacine, 402 Major depression, S45 Oxygen isotopes, 555 Major depressive disorder, 131, 713 Mania, 373 H Marijuana, 757 P MDMA, 195 Habituation, 72 Medial prefrontal cortex, 204 Panic attacks, 699 Hallucinogen, 565 Melanotransferrin, 84 Parietal lobes, S68 Haloperidol, 498 Melatonin, S92 Parkinson’s disease, 505 Heart rate, 537, S92 Memory, 690, 936 Paroxetine, 395 Heat loss, S92 Metabotropic glutamate (mGlu) receptors, Partial agonist, 789 Heat shock protein, 258 173, 505 PD 128907, 361 Heroin, 104, 320, 332 ␣-Methyl-para-tyrosine, 213 Performance, 757 Hippocampus, 1 Mice, 98 Perfusion, S79 Homeobox, 805 Microarray, S28 Perinatal, 423 Hormone pulsatility, 267 MicroCog, 757 Peripheral benzodiazepine receptors, 669 Hormones, 537 Microdialysis, 149, 662, 704 PET, 139, 476, S85 HPA axis, 267, 793, 881 Mirror system, 915 PET scan, 555, S74 HPA system, 699 Mixed states, 373 Pharmacodynamics, 165 5-HT, S40 Monoamine oxidase inhibitor (MAOI), S63 Pharmacologic treatment, 395 5-HT1B, 410 Mood regulation, S5 Pharmacological probes, S85 5-HT1D, 410 Morphine, 98 Phencyclidine, 173, 704 5-HT1A antagonist, 55 Motivation, 55 Photic stimulation, 555 5-HT receptors, 679, 871 Motor activity, 624, 690 Physical dependence, 41 5-HT1A receptors, 585, 845 Motor task, 925 Physostigmine, 555 5-HT1B receptors, 845 Muscarinic blocker, 555 Placebo-controlled, 548 5-HT2 receptors, 565 Muscle rigidity, 514 Positron emission tomography (PET), 213, 5-HT2C receptors, 585 679, 744, S50 5-HT6 receptors, 662 Postmortem, 892 5-HT1A receptor, S40 PPI, 565 ␤ N 5HT1D receptor, 608 Prefrontal, 1 Human, 555, 757 Naltrexone, 537 Prefrontal cortex, S68 Human subjects, 548 Narcolepsy, S5, S14, S21 Prepulse inhibition, 72 6-Hydroxydopamine, 204, 624 Neocortex, 816 Pretreatment anxiety, 131 5-Hydroxytryptamine (serotonin), 858 Neural, 805 Proenkephalin mRNA, 185 Hypericum perforatum, 858 Neural precursors, 816 Progesterone, 489 Hypnotics, S36 Neural transplantation, 816 Protein, 234 Hypocretin, S5, S14 Neurocognition, 766, 777 Psychometrics, 766 Hypothalamus, S21 Neurodevelopment, 423 Psychosis, 455, 936 Hypoxia, 423 Neurogenesis, 816 Psychostimulant, 118 Neuroleptics, 1, 476 Psychotic disorders, 904 Neuromuscular deficits, 690 I Neuropsychological testing, 766, 777 Neurotrophic factor, 836 R Iloperidone, 904 Nicotine, 55, 601 Immunity, S45 Nicotine gum, 313 [11C]raclopride, 213 In situ hybridization, 173, 892 Nicotine withdrawal, 313 Raloxifene, 242 In vivo binding, 213 Nimodipine, 936 Rapid eye movement sleep, S50 Indatraline, 104 NMDA, 936 Rapid tryptophan depletion, S40 Interindividual variability, S57 NMDA antagonist, 173 Rat, 195, 234, 576, 634 Intoxication, 936 NMDA receptor antagonist, 258 rCBF, 165 Intracranial self-stimulation, 55 NMDA receptors, 28, 157 Rearing, 118 Inverse agonist, 410 NMDA-antagonist, 704 Receptor autoradiography, 892 Ipsapirone, S40 N-Methyl-D-aspartate, 455 Receptor binding profile, 904 N-Methyl-D-aspartate receptor, 242 Recurrence, 332 K NonREM sleep, S57 Regeneration plasticity, 805 Noradrenaline, 204, S97 Regional blood flow, 555 Ketamine, 72, 165, 455, 936 Noradrenergic, 139 Regional cerebral blood flow, 744 Kraepelin, 373 Norepinephrine, 402 Regional glucose metabolism, 139 Norepinephrine uptake, 871 Reinforcement, 195 Nortriptyline, 737 Reinstatement, 320, 361 L Nucleus accumbens, 204, 440, 662 Relapse, 320, 332, 361 REM sleep, S85 Lateral hypothalamus, 234 Reproductive hormones, S102 Lethality, 41 O Retrospective analysis, 131 LI 160, 858 Retrosplenial cortex, 258 Light and sleep, S102 Occasion setter, 361 Reward, 55 Linkage, 608 Occupancy, 476 Ritalin®, 651 Lithium, 729 Olanzapine, 224, 468 Locomotion, 41, 118 Oleamide, S36 Locomotor activity, 440 Oligonucleotide array sequence analysis, S Locus coeruleus, 845 737 LSD, 565 Opiate withdrawal, 204 SB-271046, 662 L-type calcium channel, 936 Opioid partial agonist, 104 SCH 39166, 361

NEUROPSYCHOPHARMACOLOGY 2001–VOL. 25, NO. 6 Subject Index 953

Schizophrenia, 72, 149, 173, 402, 410, 423, Social cognition, 915 Transmembrane-4-superfamily protein, 729 455, 642, 777, 915, 936 Social isolation, 601 Transmission disequilibrium test, 608 5-5-Schizophrenia, 410 Somatic signs, 55 Treatment-resistant depression, 713 Scopolamine, 555 Spectral analysis, S57 Triazolam, 744 Seasonal affective disorder, S97 Speedball, 104 Tryptophan, 277, S40 Seasons, S97 Stem cells, 816 Tyrosine, 149 Second-order schedule, 341 Stereotypy, 118 Selective attention, 498 Stress, 320, 384, 669, 805, 836, 881 Selective serotonin reuptake inhibitors, 858 Striatum, 157, 505, 662 U Self-administration, 41, 341, 651 Stroop task, 139 Self-injurious behavior, 224 Substance abuse disorder, 651 Ultradian rhythms, 267 Sensitization, 195, 224, 384, 548, 651 Substance related disorders, 332 Sensorimotor gating, 72 Substantia nigra, 514 V Serotonin, 1, 55, 204, 277, 395, 440, 468, 679, Subtypes, 373 S40, S85 Suppression, 793 Vagus nerve stimulation, 713 Serotonin receptors, 904 Swim stress, 669 Valproate, 729 Serotonin uptake, 871 Venlafaxine, 871 Sertraline, 131 Ventral striatum, 514 Sex differences, 601, 766, 777 T Verbal learning, S68 Side effects, 713 Vigabatrin, 699, 704 SKF 81297, 361 Tamoxifen, 242, 881 Visual cortex, 555 Sleep, 576, S5, S14, S21, S36, S40, S45, S50, Targeted gene deletion, 527 S89 Terguride, 789 Sleep deprivation, S28, S68, S79 THC, 757 W Sleep EEG, S63 Theta activity, S63 Sleep onset latency, S92 Tolerance, 41, 576 Wakefulness, S63 Sleepiness, S92 Tomography, S74 Wavelet, 28 Slow wave sleep, S85 Tone decision task, 925 Withdrawal, 185, 789 Slow-wave activity, S63 Topographical assessment, 527 Women, S102 Social behavior, 277 Transgenic knockout mice, 41 Working memory, 313, 915